Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

Area soci
Non possiedi o non ricordi la password!
Clicca qui

BC: Articoli scritti da F. Bondanini

Siero o plasma? Un quesito non nuovo che attende risposte nuove
Serum or plasma? An old question awaiting for new answers.
<p>There is a continual debate on what type of sample a clinical laboratory should use. While serum is still considered the gold standard and remains the required sample matrix for some assays, laboratories must consider turn-around time, which is an important metric for laboratory performance and, more importantly, plays a critical role in patient care. In addition, a body of evidence emphasize the choice of plasma samples in order to prevent modifications of some measurands due to the coagulation process and related interferences. Advantages and disadvantages of serum and plasma are discussed on the basis of current literature and evidence. In addition, data are provided on the current utilization of the matrix (serum or plasma) in Italy and in other Countries. Finally, a rational for a possible shift from serum to plasma is provided.</p>
Biochimica Clinica ; 43(2) 178-186
Documenti - Documents
Shaping the epigenetic basis of Werner Syndrome
<p>Werner syndrome is an autosomal recessive genetic disease responsible for a progeroid disorder including a plethora of premature clinical signs traditionally associated with physiological ageing. The molecular alterations that lead to all phenotypes associated the disease remain still unidentified. Here we describe our recent findings and results from literature about the possibility that epigenetic changes could be associated with Werner syndrome phenotype. Recent literature evidences that epigenetic mechanisms are at the basis of both physiological and pathological processes, like insulin production and secretion. Analysis of genome-wide DNA methylation profile in the whole blood from patients affected by Werner syndrome demonstrated enrichment of hypermethylated probes in glycosphingolipid biosynthesis, FoxO signalling and insulin signalling pathways, while hypomethylated probes were enriched in PI3KAkt signalling and focal adhesion pathways. Twenty-two differentially methylated genes belonging to the enriched pathways resulted differentially expressed in Werner syndrome fibroblasts. DNA methylation profiles analysis in Werner syndrome patients revealed differentially methylated regions in genes involved in other ageing phenotypes or associated syndromes like systemic sclerosis, dyskeratosis congenita and Down syndrome. Genome-wide epigenetics changes observed in the peripheral blood from patients with Werner syndrome provide new insight in the pathogenesis of the disease, highlighting in some cases a functional correlation of gene expression and methylation status</p>
Biochimica Clinica ; 42(3) 210-216
Rassegne - Reviews